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A B S T R A C T
Background: Recently, ischemic stroke has emerged as a new coronary artery disease (CAD) risk
equivalent. Our purpose is to study the prevalence of CAD in ischemic stroke patients compared with
that in non-stroke patients.
Methods and results: Wemeasured coronary calcium score (CCS) in 151 ischemic stroke patients without
known CAD (stroke group) and compared it with 151 age- and sex-matched non-stroke patients (control
group). CCS was signiﬁcantly higher in the stroke group than in the control group (stroke group, median:
64, interquartile range: 3–382 vs. control group, median: 3, interquartile range: 0–65, p < 0.0001). High-
risk CAD, deﬁned as a CCS  400, was detected in 24.5% of the stroke group compared with 9.3% of the
control group (p < 0.0001). Agreement between the Framingham risk score and CCS was found in only
62 patients (41.1%). In amultiple logistic regression analysis, age [hazard ratio (HR) 1.09, 95% conﬁdence
interval (CI) 1.03–1.14], diabetes (HR 2.97, 95%CI 1.52–5.78), stroke (HR 3.85, 95%CI 1.89–7.81), andmale
sex (HR 4.41, 95%CI 1.82–0.75) were signiﬁcantly associated with high-risk CAD (p < 0.001).
Conclusions: Our results show that the prevalence of subclinical CAD in ischemic stroke patients was
high, and that a quarter of them had high-risk CAD. Age, diabetes, stroke, andmale sexwere independent
predictors of high-risk CAD.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Introduction
Coronary artery disease (CAD) is a leading cause of morbidity
and mortality in both developing and developed countries [1].
Current guidelines for the primary and secondary prevention of
cardiovascular disease, such as the American Heart Association
guidelines and the National Cholesterol Education Program Adult
Treatment Panel III guideline, deﬁne patients with coronary heart
disease (CHD) risk equivalents as those who are at the same
elevated risk as patients with ischemic heart disease [1–3]. CHD
risk equivalents include diabetes mellitus, peripheral artery
disease, carotid artery disease, and abdominal aortic aneurysm.
Recently, ischemic stroke without carotid artery disease has
emerged as a new CHD risk equivalent. Dhamoon and Elkind [4],* Corresponding author at: Department of Cardiology, Okayama Kyokuto Hospital,
567-1, Kurata, Naka-ku, Okayama 703-8265, Japan. Tel.: +81 86 276 3231;
fax: +81 86 274 1028.
E-mail address: kiwasaki@kyokuto.or.jp (K. Iwasaki).
http://dx.doi.org/10.1016/j.jjcc.2014.04.004
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsin a review of evidence from hospital- and population-based
studies, proposed that stroke could be designated as a CHD risk
equivalent, and that could be included in the outcome cluster for
absolute estimation of risks in primary and secondary prevention
[4]. More recently an American Heart Association/American
Stroke Association Scientiﬁc Statement was released [5]. This
statement concludes that patients with atherosclerotic stroke
should be included among those deemed to be at high risk (20%
over 10 years) of further atherosclerotic coronary events.
Several studies have investigated the prevalence of signiﬁcant
CAD in ischemic stroke or transient ischemic attack patients [6–8].
However, few studies measured coronary calcium score (CCS),
which is a powerful predictor of cardiac events in stroke patients
[9–11]. One study measured CCS and carotid intima–media
thickness in community-dwelling men and women with a mean
age of 80 years and found that CCS and carotid intima–media
thickness can similarly predict total cardiovascular events,
myocardial infarction, and stroke [12]. Furthermore, no study
has compared the prevalence of CAD in stroke patients with that inreserved.
Table 1
Clinical characteristics of patients.
Stroke group Control group p
n=151 n=151
Age (years) 67.37.8 67.37.8 0.9999
Sex (male) 101 (66.9%) 101 (66.9%) 0.9999
Hypertension 114 (75.5%) 81 (53.6%) <0.0001
Hyperlipidemia 86 (57.0%) 78 (51.7%) 0.3554
Diabetes 49 (32.5%) 54 (35.8%) 0.5439
Smoking 38 (25.2%) 45 (29.8%) 0.3669
Obesity 30 (19.9%) 35 (23.2%) 0.4839
Laboratory data
TC (mg/dl) 216.746.4 209.843.2 0.4515
TG (mg/dl) 147.990.6 157.996.5 0.5878
HDL-C (mg/dl) 60.715.3 61.335.8 0.8935
LDL-C (mg/dl) 126.039.6 120.229.8 0.6706
HbA1c (%) 5.700.90 5.72 0.94 0.8743
BS (mg/dl) 131.242.1 137.441.8 0.6852
Medication
Aspirin 28 (18.5%) 25 (16.6%) 0.6500
Statin 29 (19.2%) 36 (23.8%) 0.3270
CCB 61 (40.4%) 57 (37.7%) 0.6371
ACE-I/ARB 70 (46.4%) 42 (27.8%) 0.0009
b-Blocker 8 (5.3%) 6 (4.0%) 0.5841
Oral DM agent 21 (13.9%) 30 (19.9%) 0.1669
Insulin 2 (1.3%) 3 (2.0%) 0.6520
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; BS, blood sugar; CCB, calcium channel blocker; DM, diabetes mellitus;
HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.
K. Iwasaki et al. / Journal of Cardiology 65 (2015) 71–7572non-stroke patients. We therefore measured CCS in ischemic
stroke patients without known CAD and compared the results with
those of age- and sex-matched non-stroke patients.
Methods
Patients
From September 2011 through September 2012, 184 patients
with acute ischemic stroke were admitted to our hospital. The
diagnosis of ischemic stroke was made according to the National
Institute of Neurological Disorders and Stroke criteria [13]. We
measured CCS of ischemic stroke patients. The following patients
were excluded: (1) patients who died; (2) patients with disabling
stroke (modiﬁed Rankin scale score 33); (3) patients older than
80 years; (4) patients with cardioembolic stroke; (5) patients with
symptomatic carotid artery disease, deﬁned as stenosis 50% by
Duplex ultrasonography; (6) patients with known CAD; (7)
patients with atrial ﬁbrillation; or (8) patients who refused CCS
measurement. Thus, 151 patients underwent CCS measurement
(stroke group). Sixty-four patients had lacunar infarcts, 81 patients
had atherothrombotic infarcts, and 6 patients had infarcts of an
unknown type.
Over the same period, 407 non-stroke patients with coronary
risk factors but without known CAD underwent CCSmeasurement.
For inclusion in the control group, we randomly selected
151 patients from this group who were matched for age and sex
with the above 151 ischemic stroke patients.
Framingham risk score
We calculated Framingham risk score (FRS) in each patient in
the stroke group [14]. The 10-year risk ofmyocardial infarction and
cardiac death was calculated using this score. Risk was deﬁned as
follows: low, less than 10%; intermediate, between 10% and 20%; or
high, greater than 20%.
64-Multidetector computed tomography
All patients were scanned with a 64-multidetector computed
tomography (64-MDCT) system (SOMATOM Sensation 64 Cardiac;
Siemens Medical Solutions, Erlangen, Germany). A native scan
without contrast dye was performed to determine the total
calcium burden of the coronary tree (sequential scan with
32-mm  0.6-mm collimation, tube current 60 mA s at 120 kV).
A total of 64 overlapping 3.0-mm slices per rotation were acquired
using a focal spot, periodically moving longitudinally (z-ﬂying
focal spot). The tube current was modulated according to the
electrocardiogram (ECG), with a maximum current of 200 mA s
during a period of approximately 330 ms centered at 375 ms
before the next R-wave, and reduced by 80% during the remaining
cardiac cycle (care dose system).
64-MDCT image interpretation
CT data setswere transferred to an ofﬂineworkstation (Aquarius
NetStation, Terarecon Inc., San Maeteo, CA, USA) for image analysis.
One physician measured CCS in the right coronary artery, left main
trunk, left anterior descending coronary artery, and left circumﬂex
coronary artery, then calculated the total CCS with dedicated
software. The results were expressed as Agatston score [15]. In
40 patients, inter-observer and intra-observer variability were low
(interquartile range of 0–5%). We used the usual CCS risk
classiﬁcation deﬁnitions. Low risk was deﬁned as a CCS between
0 and 99, intermediate risk was deﬁned as a CCS between 100 and
399, and high riskwas deﬁned as a CCS equal to or greater than 400.We studied the difference in CCS between the two groups and
the relationship between the FRS and the CCS in the stroke group.
We also performed univariate andmultivariate analyses to identify
factors associated with high-risk CCS (CCS  400).
Informed consent for clinical procedures and the research
protocol was received from all patients studied. The study was
approved by an institutional review board.
Statistical analysis
Data are expressed as mean  SD. Continuous laboratory
variables were compared using two-group t-test. Because the CCS
data did not show a normal distribution, the Mann–Whitney test was
used to determine differences between the two groups. Discrete
variables were expressed as counts or percentages and were
compared using the chi-square test or Fisher’s exact test. The
relationship between a high-risk CCS and patient characteristics was
assessed using univariate and multivariate analyses. We performed a
multiple logistic regression analysis that included all variables with a
value of p < 0.05 in the univariate analysis. A p-value <0.05 was
considered statistically signiﬁcant.
Results
Clinical characteristics of the studied patients are shown in
Table 1. Because of the selection criteria, age and the prevalence of
male patients were the same in each group. The prevalence of
hypertension was signiﬁcantly higher in the stroke group, while
the prevalence of hyperlipidemia, diabetes, smoking, and obesity
was not signiﬁcantly different between the two groups. Laboratory
data were also not signiﬁcantly different between the two groups.
Regarding patientmedication use, angiotensin-converting enzyme
inhibitor and angiotensin receptor blocker use were more
prevalent in the stroke group. The use of other medications was
not signiﬁcantly different between the two groups.
Fig. 1 shows the CCS of the two groups. The CCS was
signiﬁcantly higher in the stroke group than in the control group
(median: 64, interquartile range: 3–382 in the stroke group vs.
[(Fig._1)TD$FIG]
Fig. 1. The coronary artery calcium score of the stroke group and control group. CCS,
coronary calcium score.
Table 2
Coronary calcium score in stroke and control group.
Stroke group Control group p
n=151 n=151
0 35 (23.2%) 72 (47.7%)
1–99 50 (33.1%) 48 (31.8%)
100–399 29 (19.2%) 17 (11.2%)
400–999 16 (10.6%) 9 (6.0%)
1000 21 (13.9%) 5 (3.3%) <0.0001
Table 4
The results of univariate analysis associated with high risk coronary calcium score.
CCS<400 CCS400 p
n=251 n=51
Age 66.77.9 70.16.4 0.0043
Sex (male) 158 (62.9%) 44 (86.3%) 0.0013
Hypertension 155 (61.8%) 40 (78.4%) 0.0232
Hyperlipidemia 138 (55.0%) 26 (51.0%) 0.6012
Diabetes 76 (30.3%) 27 (52.9%) 0.0019
Stroke 114 (45.4%) 37 (72.5%) 0.0004
Smoking 65 (25.9%) 18 (35.3%) 0.1705
Obesity 52 (20.7%) 13 (25.5%) 0.4496
Laboratory data
TC (mg/dl) 214.048.5 211.042.2 0.7010
TG (mg/dl) 157.293.5 161.4165.1 0.8272
HDL-C (mg/dl) 55.815.4 58.016.4 0.3985
LDL-C (mg/dl) 128.842.2 122.030.5 0.3436
HbA1c (%) 6.011.37 6.231.41 0.3348
BS (mg/dl) 140.259.1 140.957.1 0.9374
BS, blood sugar; CCS, coronary calcium score; HbA1c, hemoglobin A1c; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholester-
ol; TC, total cholesterol; TG, triglyceride.
Table 5
The results of multiple logistic regression analysis associated with high-risk
coronary calcium score.
Variable OR 95%CI p
Age 1.09 1.03–1.14 0.001
Diabetes 2.97 1.52–5.78 0.001
Stroke 3.85 1.89–7.81 0.001
Sex (male) 4.41 1.82–10.75 0.001
CI, conﬁdence interval; OR, odds ratio.
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p < 0.0001).
Table 2 shows the distribution of CCS in the two groups.
Signiﬁcantly more patients in the stroke group had a higher CCS
(p < 0.0001). No coronary calcium was detected in 23.2% of the
stroke group compared with 47.7% of the control group. High-risk
CAD, deﬁned as a CCS  400, was detected in 24.5% of the stroke
group compared with 9.3% of the control group.
Table 3 shows the relationship between FRS and CCS in the
stroke group. Among 151 patients in the stroke group, 39, 71, andTable 3
Framingham risk score and coronary calcium score.
Framingham risk score Coronary calcium score
low risk 39 (25.8%) low risk 32 (82.1%)
intermediate risk 6 (15.4%)
high risk 1 (2.5%) 
intermediate risk  71 (47.0%) low risk 37 (52.1%)
intermediate risk 14 (19.7%)
high risk 20 (28.2%)
high risk 41 (27.2%) low risk 16 (39.0%)
intermediate risk 9 (22.0%)
high risk 16 (39.0%)41 patients were classiﬁed as low, intermediate, and high risk,
respectively, according to the FRS. However, risk classiﬁcation
according to CCS showed different results. The CCS identiﬁed 82.1%
of patients with a low risk FRS as low risk. However, it identiﬁed
intermediate and high risks in only 19.7% and 39.0% of patients
with intermediate and high risk FRS, respectively. Thus, agreement
between the FRS and the CCSwas found in only 62 patients (41.1%).
Table 4 shows the results of a univariate analysis of factors
associated with a high-risk CCS. Age, prevalence of male sex,
hypertension, diabetes, and stroke were signiﬁcantly higher in
patients with a CCS  400 than in those with a CCS < 400.
Laboratory data were not signiﬁcantly different between the
two groups. In a multiple logistic regression analysis adjusted for
variables associated with a high-risk CCS (CCS  400), age,
diabetes, stroke, and male sex were signiﬁcantly associated with
a high-risk CCS (Table 5).
Discussion
Our results show that the prevalence and severity of CAD were
higher in stroke patients without known CAD compared with age-
and sex-matched non-stroke patients. Almost 80% of stroke
patients had CAD detected by the CCS compared with 50% of
non-stroke patients. About a quarter of stroke patients had high-
risk CAD (CCS  400), whereas less than 10% of non-stroke patients
had high-risk CAD. Thus, the prevalence of high-risk CADwasmore
than twofold in stroke patients compared with non-stroke
patients. To our knowledge, this is the ﬁrst study that measured
CCS in stroke patients without known CAD and compared it with
the CCS of non-stroke patients.
A number of previous studies investigated the prevalence of
CAD in stroke patients. Yoo et al. [6] performed coronary computed
tomography angiography (CCTA) in 1304 stroke patients. They
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of CAD in this population were 32.3% and 70.1%, respectively.
Hoshino et al. [7] studied 104 patients with cerebral infarction.
CCTA showed a prevalence of signiﬁcant CAD of 37.5% in this
group. Calvet et al. [8] performed CCTA in 274 patients with non-
disabling, non-cardioembolic ischemic stroke or transient ische-
mic attack and no knownCAD. They found signiﬁcant CAD in 18% of
patients. Thus, previous studies have shown that 20–40% of stroke
patients have asymptomatic signiﬁcant CAD.
However, many studies have shown that most cases of
myocardial infarction and sudden cardiac death do not arise from
the sites of signiﬁcant coronary narrowing, and that coronary
revascularization therapy of coronary obstruction in patients with
stable CAD does not reduce the risk of myocardial infarction or
cardiac death [16–19]. These observations are explained by the
concept of vulnerable plaque, and 70–80% of acute coronary events
result from coronary lesions that are not hemodynamically
signiﬁcant or ﬂow limiting before the event [20].
We therefore measured CCS in stroke patients. Coronary artery
calciﬁcation signiﬁes the presence of coronary atherosclerosis and
a strong linear correlation exists between total coronary artery
atherosclerotic plaque burden and the extent of coronary artery
calciﬁcation [21–23]. Coronary artery calciﬁcation has been found
to be the most powerful predictor of cardiac events, providing
independent and incremental information over risk factor-based
assessments of asymptomatic patients [9–11]. In 4129 patients
from the Heinz Nixdorf Recall study without known CAD,
traditional risk factors and CCS were measured [10]. Adding CCS
to FRS categories improved the area under curve (AUC) from 0.681
to 0.749 (p < 0.003). More recently, in the Multi-Ethnic Study of
Atherosclerosis study, 1330 patients with intermediate risk
underwent six tests of risk markers (CCS, brachial ﬂow-mediated
dilatation, ankle-brachial index, intima–media thickness, family
history, and high-sensitivity C-reactive protein) andwere followed
up for 7.6 years [11]. CCS afforded the highest increment (AUC
0.623 vs. 0.784), while brachial ﬂow-mediated dilatation had the
least (0.623 vs. 0.639). Thus, CCS provided superior discrimination
and risk reclassiﬁcation compared with other risk markers. In
contrast, patients without detectable calcium have a low rate of
coronary death or myocardial infarction over 3–5 years of
observation [10,24]. Therefore, the measurement of CCS rather
than the detection of signiﬁcant CAD would be a more rational
choice for the risk stratiﬁcation of asymptomatic CAD in stroke
patients. Our results showed that a quarter of stroke patients had
high-risk CAD (CCS  400), which was more than twofold higher
than the prevalence in non-stroke patients. In addition, the
multivariate analysis showed that age, diabetes, stroke, and male
sex were independently associated with high-risk CAD.
Our study also showed that coronary risk score had limited
ability for risk stratiﬁcation. The CCS identiﬁed low risk in most of
thepatientswith lowriskFraminghamscores.However, it identiﬁed
intermediate and high risks in only 20% and 40% of patients with
intermediate- and high-risk Framingham scores, respectively.
Agreement between scores was achieved in only 41.1% of them.
In about half of the patients with an intermediate risk, Framingham
score moved to a low-risk category according to CCS. About 40% of
patientswithahigh-riskFraminghamscorealsomoved toa low-risk
category.We think this fact has a clinically signiﬁcant impact on the
management of these patients, because these patients do not need
further examination, such as CCTA, myocardial perfusion imaging,
and coronary angiography, for risk stratiﬁcation.
Research has revealed the limitations of coronary risk scores.
Karimet al. [25]measured subclinical atherosclerosis in 498healthy
subjects, 69% ofwhomhad evidence of subclinical atherosclerosis in
more than one of the three vascular beds. Of the 68 subjects with
subclinical atherosclerosis in all three vascular beds, only 23% had ahigh risk FRS. Ahmadi et al. [26] investigated the mortality risk
associated with CCS and FRS in 730 subjects classiﬁed as low risk
versus high risk based on FRS. The mortality rate was 18.5% in the
discordant low-risk group (FRS< 10% and CCS> 100), but it was
7.7% in the discordant high-risk group (FRS> 20% and CCS = 0).
Therefore, a growing body of evidence supports the fact that global
risk scores may be useful guides in predicting long-term cardiovas-
cular disease risk in healthy populations, but are often suboptimal
for individual risk estimation [27].
There are several limitations to our study. First, the number of
patients was relatively small. To compensate for this limitation, we
selected age- and sex-matched non-stroke patients evaluated in the
same period and compared these patients with the stroke patients.
Second, we excluded patients who had died, patients who had
disabling stroke, and patients older than 80 years. Thus, it is likely
that because of these exclusions, the CCS of stroke patients was
underestimated. Third, CCS is a surrogate for CAD and represents
coronary plaque burden, not coronary artery stenosis. In addition, a
lowCCSdoesnot excludeCAD [28]. Fourth, our studydidnot include
patients with cardioembolic stroke. Cardioembolic stroke can be
expected to be associated with a higher likelihood of CAD, probably
due to the underlying presence of cardiac disease. One study found
signiﬁcant CAD in 21% of patients with suspected embolic stroke by
CCTA, which is similar to that observed in those with non-
cardioembolic stroke [29]. We excluded cardioembolic patients
because the number of patients was small and many patients had
disabling strokes. Fifth, we excluded patients with carotid artery
diseasebecause carotid arterydisease is alreadydesignatedasaCHD
equivalent. Symptomatic carotid artery disease probably accounts
for no more than 10% of patients with ischemic stroke [30].
In conclusion, our study showed that the prevalence of
asymptomatic CAD in ischemic stroke patients without known
CAD was high, and that a quarter of them had high-risk CAD
deﬁned as a CCS  400. Age, diabetes, stroke, and male sex were
independent predictors of high-risk CAD. Thus, these results
suggest that the assessment of CAD in asymptomatic ischemic
stroke patients is worthwhile.
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